The study of oral BHV-3000 (Rimegepant) for the acute treatment of chronic rhinosinusitis

The purpose of this study is to compare the efficacy and safety of rimegepant versus placebo in the acute treatment of chronic rhinosinusitis (CRS) with and without nasal polyps.

It is planned to include 200 participants.

Actual study start date is February 17, 2022. The researchers expect to complete the study by February 2023.

One primary outcome measure is to evaluate the efficacy of rimegepant compared with placebo in the acute treatment of chronic rhinosinusitis with or without nasal polyps, mean change from baseline of facial pain/pressure/fullness on Numeric Rating Score (NRS) (0-10) score.

Further details can be found here https://ichgcp.net/clinical-trials-registry/NCT05248997.

Clinical Research News

Upcoming Clinical Trials

3